American Gene Technologies

American Gene Technologies is a private, clinical-stage biotech pioneering gene and cell therapies with a core lentiviral vector platform. Its most advanced program, AGT103-T for an HIV cure, has completed a Phase 1 trial and received FDA Fast Track designation, demonstrating early safety and signals of reservoir reduction. The company is also developing an immuno-oncology approach (ImmunoTox) for solid tumors and a gene therapy for PKU, which holds Orphan Drug status. AGT operates as a platform company aiming to reduce the time and cost of developing new genetic medicines.

Proprietary lentiviral vector platform for generating autologous cell products, with patented applications for HIV cell therapy and activation of gamma delta T cells for cancer immunotherapy (ImmunoTox).

AGT operates in highly competitive arenas. The HIV cure space includes major players like Gilead and numerous academic consortia, while the immuno-oncology field is crowded with novel T-cell engagers and cell therapies. Its success will depend on demonstrating superior efficacy, safety, or manufacturing advantages with its lentiviral platform and specific cell engineering approaches.